The treatment of bone metastases is a thorny issue. Immunotherapy may be one of the few
hopes for patients with unresectable bone metastases. Immune checkpoint inhibitors are the …

Liver metastasis is a frequent phenomenon in advanced tumor disease. Immune checkpoint
inhibitors (ICIs) are a new class of therapeutics that can improve the prognosis of cancer …

Background Immunotherapy‐antiangiogenesis combination therapy has achieved excellent
survival outcomes in hepatocellular carcinoma (HCC) in clinical trials. However, the …

We conducted a retrospective study to evaluate the efficacy of immune checkpoint inhibitor
(ICI) rechallenge in patients with advanced non-small cell lung cancer (NSCLC). The study …

Purpose This study was performed to investigate the efficacy and safety of combined
immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer …

Aims: To clarify the relationship between the potency of dual blockade of PD-1 or its ligand
(PD-L1) plus CTLA-4 and patients with different clinical characteristics with solid tumors, the …

Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …

The gut microbiome is essential for regulating host metabolism, defending against
pathogens, and shaping the host's immune system. Mounting evidence highlights that …

Immune checkpoint molecules, such as programmed cell death 1 (PD‑1) and programmed
cell death ligand 1 (PD‑L1), have a critical role in regulating immune responses, including in …

Once cancer metastasizes to the bone, the prognosis of cancer patients becomes extremely
poor. Unfortunately, the current most successful treatment for bone metastasis can extend …